Chronic treatment with insulin-like growth factor I enhances myocyte contraction by upregulation of Akt-SERCA2a signaling pathway
- 1 July 2008
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 295 (1) , H130-H135
- https://doi.org/10.1152/ajpheart.00298.2008
Abstract
Chronic treatment with insulin-like growth factor I (IGF-I) improves contractile function in congestive heart failure and ischemic cardiomyopathy. The present study investigated the effect of chronic treatment with IGF-I on intrinsic myocyte function and the role of the phosphatidylinositol (PI)3-kinase-Akt-sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)2a signaling cascade in these responses. Myocytes were isolated from 23 adult rats and cultured with and without IGF-I (10−6M). After 48 h of treatment, myocyte function was evaluated. IGF-I increased contractile function (percent contraction, 7.7 ± 0.3% vs. 4.5 ± 0.3%; P < 0.01) and accelerated relaxation time (time for 70% relengthening, 81 ± 4 vs. 106 ± 5 ms; P < 0.05) compared with untreated myocytes [control (Con)]. The enhanced function was associated with an increase in Ca2+transients assessed by fura-2 (340/380 nm; IGF-I, 0.42 ± 0.02 vs. Con, 0.25 ± 0.01; P < 0.01). The PI3-kinase inhibitor LY-249002 (10−9M) abolished the enhanced function caused by IGF-I. IGF-I increased both Akt and SERCA2a protein levels 2.5- and 4.8-fold, respectively, compared with those of Con ( P < 0.01); neither phospholamban nor calsequestrin was affected. To evaluate whether the SERCA2a protein was directly mediated by Akt-SERCA2a signaling, IGF-I-induced changes in the SERCA2a protein were compared in myocytes transfected with adenovirus harboring either constitutively active Akt [multiplicity of infection (MOI), 15] or dominant negative Akt (dnAkt; MOI, 15). The ability of IGF-I to upregulate the SERCA2a protein in myocytes transected with active Akt was absent in dnAkt myocytes. Taken together, our findings indicate that chronic treatment with IGF-I enhances intrinsic myocyte function and that this effect is due to an enhancement in intracellular Ca2+handling, secondary to the activation of the PI3-kinase-Akt-SERCA2a signaling cascade.Keywords
This publication has 39 references indexed in Scilit:
- Influence of cardiac‐specific overexpression of insulin‐like growth factor 1 on lifespan and aging‐associated changes in cardiac intracellular Ca2+ homeostasis, protein damage and apoptotic protein expressionAging Cell, 2007
- Cardiac-specific overexpression of insulin-like growth factor 1 attenuates aging-associated cardiac diastolic contractile dysfunction and protein damageAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Mechanism of Enhanced Cardiac Function in Mice with Hypertrophy Induced by Overexpressed AktJournal of Biological Chemistry, 2003
- Insulin-Like Growth Factor-1 Exerts Ca 2+ -Dependent Positive Inotropic Effects in Failing Human MyocardiumCirculation Research, 2003
- Altered Excitation–Contraction Coupling in Myocytes from Remodeled Myocardium after Chronic Myocardial InfarctionJournal of Molecular and Cellular Cardiology, 2002
- Insulin-like Growth Factor I as aÈCardiac Hormone: Physiological and Pathophysiological Implications in Heart DiseaseJournal of Molecular and Cellular Cardiology, 1999
- Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytesCardiovascular Research, 1999
- Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathyThe Lancet, 1998
- Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure.Journal of Clinical Investigation, 1995
- Upregulation of IGF1, IGF1‐receptor, and late growth related genes in ventricular myocytes acutely after infarction in ratsJournal of Cellular Physiology, 1994